BridgeBio Pharma (BBIO) Competitors

Biohaven (NYSE:BHVN) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk, community ranking and valuation.

Which has more risk and volatility, BHVN or BBIO?

Biohaven has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.

Which has better earnings and valuation, BHVN or BBIO?

Biohaven has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	$462.51M	9.68	-$408.17M	-$6.83	-7.43
BridgeBio Pharma	$219.12M	21.67	-$643.20M	-$3.22	-7.88

Is BHVN or BBIO more profitable?

Biohaven has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -207.11%. BridgeBio Pharma's return on equity of 0.00% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-212.83%	-157.42%
BridgeBio Pharma	-207.11%	N/A	-76.71%

Does the MarketBeat Community believe in BHVN or BBIO?

Biohaven received 233 more outperform votes than BridgeBio Pharma when rated by MarketBeat users. However, 70.04% of users gave BridgeBio Pharma an outperform vote while only 66.67% of users gave Biohaven an outperform vote.

Company	Underperform	Outperform
Biohaven	Outperform Votes 392 66.67%	Underperform Votes 196 33.33%
BridgeBio Pharma	Outperform Votes 159 70.04%	Underperform Votes 68 29.96%

Does the media favor BHVN or BBIO?

In the previous week, Biohaven had 6 more articles in the media than BridgeBio Pharma. MarketBeat recorded 11 mentions for Biohaven and 5 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.86 beat Biohaven's score of 0.53 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders hold more shares of BHVN or BBIO?

88.8% of Biohaven shares are held by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are held by institutional investors. 16.0% of Biohaven shares are held by company insiders. Comparatively, 24.7% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Do analysts recommend BHVN or BBIO?

Biohaven currently has a consensus price target of $61.92, suggesting a potential upside of 22.05%. BridgeBio Pharma has a consensus price target of $47.92, suggesting a potential upside of 88.80%. Given BridgeBio Pharma's higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	0 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	3.07
BridgeBio Pharma	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

Biohaven beats BridgeBio Pharma on 10 of the 19 factors compared between the two stocks.